# Onchilles Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onchilles-pharma

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.onchillespharma.com
- Total disclosed funding: $32M
- Latest round: Series A (Nov 7, 2025)
- Investors on record: 6

## About

Based in California, US, and founded in 2017, Onchilles Pharma, Inc. operates as a biotechnology company that develops first-in-class drug candidates. The company was co-founded by Court R. Turner and Lev Becker and is backed by Series A investors Lyzz Capital and UChicago Startup Investment Program in June 2021.

The company's line of product includes ELANE (Elastase, Neutrophil Expressed) is a new treatment paradigm that helps to kills cancer cells regardless of genetic mutation or anatomical origin.

Onchilles Pharma plans to advance the first drug candidate through preclinical proof-of-concept and interrogate the novel pathway for further pipeline development.

## Funding rounds

- Series A, Nov 7, 2025, $25M — Lincoln Park Capital, Lyzz Capital, Kennedy Lewis Investment Management, InVivium Capital, UCM Ventures
- Series A, Jun 10, 2021, $7M — Lincoln Park Capital, Lyzz Capital, UChicago Startup Investment Program

## Investors

- Lincoln Park Capital — Series A
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series A
- UChicago Startup Investment Program — Series A
- Kennedy Lewis Investment Management — Series A
- InVivium Capital (https://capitalatlas.ai/funds/invivium-capital) — Series A
- UCM Ventures — Series A